Arrhythmias in Pulmonary Arterial Hypertension

Progress in Cardiovascular Diseases

Volumn 55, Issue 2, 2012, Pages 180-186

  Rajdev, Archana ^a   Garan, Hasan ^b   Biviano, Angelo ^b  

^a DANBURY HOSPITAL   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Arrhythmia; Pulmonary artery hypertension; Supraventricular tachycardia; Ventricular tachycardia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; FLECAINIDE; PROPAFENONE; SOTALOL;

ARTICLE; BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; CATHETER ABLATION; CONNECTIVE TISSUE DISEASE; DEFIBRILLATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EISENMENGER COMPLEX; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART AUTOMATICITY; HEART MUSCLE ISCHEMIA; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; OUTCOME ASSESSMENT; POPULATION RISK; PULMONARY HYPERTENSION; RESUSCITATION; RISK ASSESSMENT; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ARRHYTHMIAS, CARDIAC; CARDIAC PACING, ARTIFICIAL; CATHETER ABLATION; DEATH, SUDDEN, CARDIAC; HEART RATE; HUMANS; HYPERTENSION, PULMONARY;

EID: 84866624147     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2012.06.002     Document Type: Article

References (42)

1. Simonneau G., Robbins I., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43-S54.
2. Pietra G.G., Capron F., Tuder R.M., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004, 43:S25-S32.
3. Morrell N.W., Adnot S., Archer S.L., et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:S20-S31.
4. James T.N. On the cause of syncope and sudden death in primary pulmonary hypertension. Ann Intern Med 1962, 56:252-264.
5. Kanemoto N., Sasamoto H. Arrhythmias in primary pulmonary hypertension. Jpn Heart J 1979, 20:765-775.
6. Folino A.F., Bobbo F., Schiraldi C., et al. Ventricular arrhythmias and autonomic profile in patients with primary pulmonary hypertension. Lung 2003, 181:321-328.
7. Schrier R.W., Bansal S. Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure?. Clin J Am Soc Nephrol 2008, 3:1232-1237.
8. Algra A., Tijssen J.G., Roelandt J.R., et al. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation (N.Y.N.Y.) 1991, 83:1888-1894.
9. Hong-Liang Z., Qin L., Zhi-hong L., et al. Heart rate-corrected QT interval and QT dispersion in patients with pulmonary hypertension. Wien Klin Wochenschr 2009, 121:330-333.
10. Tongers J., Schwerdtfeger B., Klein G., et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007, 2007:127-132.
11. Ruiz-Cano M.J., Gonzalez-Mansilla A., Escribano P., et al. Clinical implications of supraventricular arrhythmias in patients with severe pulmonary arterial hypertension. Int J Cardiol 2011, 146:105-106.
12. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
13. Mathur P.N., Powles P., Pugsley S.O., et al. Effect of digoxin on right ventricular function in severe chronic airflow obstruction. A controlled clinical trial. Ann Intern Med 1981, 95:283-288.
14. Showkathali R., Tayebjee M.H., Gibbs S.R., et al. Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension. Int J Cardiol 2011, 149:279-280.
15. Tateno S., Niwa K., Nakazawa M., et al. Risk factors for arrhythmia and late death in patients with right ventricle to pulmonary artery conduit repair-Japanese multicenter study. Int J Cardiol 2006, 106:373-381.
16. Humbert M. A critical analysis of survival in idiopathic pulmonary arterial hypertension. Presse Med 2010, 39:1S41-1S45.
17. McLaughlin V.V. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 2011, 20:262-269.
18. Arena V., De Giorgio F., Abbate A., et al. Fatal pulmonary arterial dissection and sudden death as initial manifestation of primary pulmonary hypertension: a case report. Cardiovasc Pathol 2004, 13:230-232.
19. Hoeper M.M., Galié N., Murali S., et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002, 165:341-344.
20. Galie N., Fracchia C., Magnani B., et al. Myocardial perfusion abnormalities of the right ventricle in patients with severe precapillary pulmonary hypertension (abstract. Am J Respir Crit Care Med 1998, 157:A593.
21. Grant S.M., Goa K. Iloprost-a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs 1992, 43:889-924.
22. Handoko M.L., de Man F.S., Allaart C.P., et al. Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart. Eur Respir Rev 2010, 19:72-82.
23. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e385-e484.
24. Handoko M.L., Lamberts R.R., Redout E.M., et al. Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. Am J Physiol Heart Circ Physiol 2009, 297:H1752-H1759.
25. Hardziyenka M., Surie S., de Groot J.R., et al. Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: an open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension. Europace 2011, 13:1753-1759.
26. Motonaga K.S., Miyake C.Y., Rosenthal D.N., et al. Is there a role for cardiac resynchronization therapy in pediatric pulmonary hypertension?. J Heart Lung Transplant 2012, 31:S4-S29.
27. McLaughlin V.V., Presberg K.W., Doyle R.L., et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126:78S-92S.
28. Saha A., Balakrishnan K.G., Jaiswal P.K., et al. Prognosis for patients with Eisenmenger syndrome of various aetiology. Int J Cardiol 1994, 45:199-207.
29. Semizel E., Alehan D., Ozer S., et al. Eisenmenger syndrome: identifying the clues for arrhythmia. Anadolu Kardiyol Derg 2008, 8:32-37.
30. Cantor W.J., Harrison D.A., Moussadji J.S., et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol 1999, 84:677-681.
31. Young D., Mark H. Fate of the patient with the Eisenmenger syndrome. Am J Cardiol 1971, 28:658-669.
32. Triedman J.K., Alexander M.A., Walsh E.P., et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial tachycardia in patients with congenital heart disease. J Am Coll Cardiol 2002, 39:1827-1835.
33. Gregoratos G., Abrams J., Epstein A.E., et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices. J Am Coll Cardiol 2002, 40:1703-1719.
34. Patanè S., Marte F., Sturiale M., et al. Atrial flutter, ventricular tachycardia and changing axis deviation associated with scleroderma. Int J Cardiol 2011, 153:e25-e28.
35. Morelli S., Piccirillo G., Fimognari F., et al. Twenty-four hour heart period variability in systemic sclerosis. J Rheumatol 1996, 23:643-645.
36. Sgreccia A., Morelli S., Ferrante L., et al. QT interval and QT dispersion in systemic sclerosis (scleroderma). J Intern Med 1998, 243:127-132.
37. Paradiso M., Gabrielli F., Coppotelli L., et al. Signal-averaged electrocardiography and echocardiography in the evaluation of myocardial involvement in progressive systemic sclerosis. Int J Cardiol 1996, 53:171-177.
38. Morelli S., Sgreccia A., De Marzio P., et al. Noninvasive assessment of myocardial involvement in patients with systemic sclerosis: role of signal averaged electrocardiography. J Rheumatol 1997, 24:2358-2363.
39. Kostis J.B., Seibold J.R., Turkevich D., et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med 1988, 84:1007-1015.
40. Gallagher J.J., Anderson R.W., Kasell J., et al. Cryoablation of drug-resistant ventricular tachycardia in a patient with a variant of scleroderma. Circulation 1978, 57:190-197.
41. Bulkley B.H., Klacsmann P.G., Hutchins G.M. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteriesa clinicopathological study of 9 patients with progressive systemic sclerosis. Am Heart J 1978, 95:563-569.
42. Rankin A.C., Osswald S., Garan H., et al. Mechanism of sustained monomorphic ventricular tachycardia in systemic sclerosis. Am J Cardiol 1999, 83:633-636.